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Abstract 
A systematic understanding of the evolution and growth dynamics of invasive solid tumors in 
response to different chemotherapy strategies is crucial for the development of individually optimized 
oncotherapy. Here, we develop a hybrid three-dimensional (3D) computational model that integrates 
pharmacokinetic model, continuum diffusion-reaction model and discrete cell automaton model to 
investigate 3D invasive solid tumor growth in heterogeneous microenvironment under chemotherapy. 
Specifically, we consider the effects of heterogeneous environment on drug diffusion, tumor growth, 
invasion and the drug-tumor interaction on individual cell level. We employ the hybrid model to 
investigate the evolution and growth dynamics of avascular invasive solid tumors under different 
chemotherapy strategies. Our simulations reproduce the well-established observation that constant 
dosing is generally more effective in suppressing primary tumor growth than periodic dosing, due to 
the resulting continuous high drug concentration. In highly heterogeneous microenvironment, the 
malignancy of the tumor is significantly enhanced, leading to inefficiency of chemotherapies. The 
effects of geometrically-confined microenvironment and non-uniform drug dosing are also 
investigated. Our computational model, when supplemented with sufficient clinical data, could 
eventually lead to the development of efficient in silico tools for prognosis and treatment strategy 
optimization. 
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1. Introduction 
Cancer is a group of highly fatal diseases that usually involve abnormal cell growth and emergent 
migration behaviors due to complex tumor-host interactions, leading to invasion and metastasis. For a 
typical solid tumor, the proliferative cells take up oxygen and nutrition from surrounding 
microenvironment and actively produce daughter cells to expand the tumor mass. The cells in the 
inner region of the tumor become inactive (quiescent) due to starving and eventually turn necrotic. In 
malignant tumors, mutant daughter cells with invasive phenotype i.e., low cell-cell adhesion, high 
mobility and strong drug resistance, are produced and can detach from the primary tumor and migrate 
into the surrounding stromal 1-4. Such invasive cells can enter the circulation systems (e.g., blood 
vessels) and reside in distant organs, leading to the emergence of secondary tumor and metastasis, and 
thus makes it very difficult for cancer treatment.5   
To better understand the evolution and invasive of malignant tumors and the influence of the 
host microenvironment, a variety of computational models on tumor growth have been devised, which 
can be generally categorized continuum 6-14, discrete 15-20 and hybrid 21-26 models, to name but a few. 
The continuum models typically employ coupled partial differential equations (e.g., diffusion-reaction 
equations) characterizing tumor population evolution in homogeneous microenvironment as well as 
the evolution oxygen and nutrient concentrations due to cancer cell consumption and metabolism. The 
continuum models are able to capture the complex diffusion dynamics of the nutrients, the tumor 
growth and cell apoptosis as well as the effects of chemotaxis and cell adhesion, and can be easily 
employed to investigate large systems containing millions of cancer cells in the mature tumor. 
However, the detailed evolution and phenotype heterogeneity of individual tumor cells cannot be 
studied using the continuum models.    
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In the discrete models, individual tumor cells are explicitly considered and the tumor system 
can be represented using either the particle-assembly model20 or the cellular automaton (CA) 
model15-19. In the particle-assembly model, each tumor cell is represented as a bag of incompressible 
fluid enclosed by a hyper-elastic membrane with prescribed properties, which can capture detailed 
morphology evolution of the entire proliferative colony. In the CA model, the simulation domain is 
pre-tessellated into “automaton cells”, and each automaton cell is assigned a value representing either 
a biological cell in a particular state (e.g., proliferative, quiescent or necrotic) or a region of host 
microenvironment. The state of a specific automaton cell depends on those of the neighboring cells 
via prescribed CA rules. The original CA models were devised to simulate the proliferative growth of 
brain tumors 16 and have been recently generalized to investigate phenotype heterogeneity, invasive 
growth 27,28, effects of confined heterogeneous environment 15,28, angiogenesis 17,22, and tumor 
dormancy 29. The hybrid models typically integrate the continuum model for nutrient concentration 
evolution and the CA model for individual cell dynamics, explicitly considering the coupling of the 
two via nutrients up-take and consumption for cell proliferation21-24. Due to the computational cost, 
most existing hybrid models are focused on 2D systems. The readers are referred to recent reviews for 
a more detailed discussion of the aforementioned tumor simulation models.30-33 
An outstanding issue in oncotherapy is the lacking of a systematic understanding of the 
evolution and growth dynamics of invasive solid tumors in response to different chemotherapy 
strategies. Such an understanding is crucial for the development of individually optimized 
oncotherapy. Typical chemotherapeutic agents (drugs) interfere with cancer cell division (mitosis) to 
cause cell damage or death, suppressing the overall growth of the tumor34,35. Generally, drug 
macromolecules are transported to the tumor site via diffusion in the stromal and then up-taken by the 
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tumor cells. The effectiveness of chemotherapy strongly depends on the drug concentration around the 
tumor cells. However, a high drug concentration also damages normal and healthy tissue cells, leading 
to significant side effects for the patient. An optimized dosing strategy that can result in efficient 
elimination of tumor cells while maintaining the integrity and functionality of normal healthy tissues 
is crucial to the success of the cancer treatment. Periodic dosing has recently been suggested as a 
promising treatment strategy 36. In order to maximize the treatment effectiveness, the heterogeneity of 
the tumor-host system37,38 as well as the variation in the drug’s cytotoxicity (cell killing) and the 
effects of tumor hypoxia 34,35 should also be taken into account.  
In most chemotherapy, the anti-tumor drugs are either absorbed in the digestion system or 
directly injected into the circulation systems, and then transported different organs and tumor sites by 
the blood vessels. The drugs then diffuse into the avascular tissues while being metabolized by cells. 
The evolution of average drug concentrations in plasma, interstitial tissues and different organs can be 
captured via the pharmacokinetic (PK) calculations39-41. Such PK calculations involve master ordinary 
different equations (ODE) that take into the consumption of drugs due to decomposition and 
metabolism, as well as transport of drugs between different counterparts (e.g., organs) in the body. 
Although the PK models can provide average drug concentration in different organs, it is not able to 
describe the detail temporal-spatial evolution of drug concentration within an organ or tissue. To solve 
such temporal-spatial evolution, diffusion-reaction models are usually employed, in which the 
consumption of drugs is quantified via the “sink” terms in the associated partial differential equations 
(PDE). 
    Recently, significant research efforts have been devoted to computational modeling of various 
aspects of chemotherapy. For example, the effects of spatial heterogeneity in drug concentration42, 
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vascular structure and heterogeneous host environment7,43, cell packing density44, intrinsic 
heterogeneity in cell phenotypes and cell cycles45-50 on the effectiveness of treatment and acquired 
drug resistance51,52 have been systematically studied. Computational tools for treatment optimization 
have been devised53-56 and data-based platform has been developed to assess robustness of treatment57. 
In this work, we develop a hybrid three-dimensional computational model that integrates the 
physiologically based pharmacokinetic model, continuum diffusion-reaction model and discrete cell 
automaton model to investigate 3D invasive solid tumor growth in heterogeneous microenvironment 
under chemotherapy. In particular, we explicitly consider the effect of heterogeneous environment on 
drug diffusion, tumor growth and invasion as well as the drug-tumor interaction on individual cell 
level. We employ the hybrid model to investigate the effectiveness of two commonly used dosing 
strategies, i.e., constant and periodic dosing, in controlling the growth of avascular invasive solid 
tumors. Our model robustly reproduces the observation that constant dosing is generally more 
effective in suppressing primary tumor growth compared to periodic dosing, due to the resulting 
continuous high drug concentration58-61. However, the suppression of primary tumor progression does 
not necessarily lead to a suppression of invasive cell migration, which results in complex invasion 
branches emitting from the primary tumor62-65. Moreover, we show that microenvironment 
heterogeneity can significantly enhanced the malignancy of the tumor and thus, reduce the 
effectiveness of the chemotherapy with even periodic dosing66-69.  
2. Materials and Methods 
In our model, the computational domain is a sub-region in an organ that contains both the 
growing avascular tumor with possible invasive branches and the surrounding stroma. Specifically, 
we consider two types of the host micro-environment respectively with avascular tissues (Fig. 1(a)) 
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and with vascular tissues (Fig. 1(b)). We consider that within the simulation domain, there are no 
blood vessels and the drugs are transported to the tumor region via diffusion. The drug contraction in 
the organ will first be obtained via the physiologically based pharmacokinetic (PBPK) model and 
imposed as boundary condition at the boarder of the computational domain. 
The evolution of drug concentration within the computational domain is described by a 
diffusion-reaction equation, which includes position dependent diffusion coefficient for heterogeneous 
microenvironment and consumption terms characterizing the drug’s metabolism and decomposition. 
Different dosing strategies are simulated using different time-dependent boundary conditions. The 
evolution of the invasive solid tumor is simulated using the cellular automaton model. Specifically, 
the probability of division of each proliferative cell is now considered a function of not only the local 
microenvironment (e.g., ECM density, rigidity and pressure) but also the local drug concentration 
computed using the diffusion-reaction equation. We consider the migration an invasive cell depends 
only on the microenvironment. In the subsequent subsections, we will provide detailed descriptions of 
these models and their integration. 
2.1 Pharmacokinetic modeling of temporal-evolution of overall drug concentration  
In most chemotherapy, the anti-tumor drugs are either absorbed in the digestion system or directly 
injected into the circulation systems, and then transported to different organs and tumor sites by the 
blood vessels. The decay of average drug concentrations over time in different organs (due to 
transport of drugs among different organs and drug consumption) is usually described by a set of 
coupled ordinary differential equations referred to as the physiologically based pharmacokinetic 
(PBPK) models 39,41,70. Here, we apply a two-compartment PBPK model, in which the drug 
concentrations in a vascularized compartment (C1) and the concentration in an avascular compartment 
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(C2) are considered. For the vascularized compartment, e.g., a tumor micro-environment with a high 
density of blood vessels in the stromal tissue, the transport of drugs is mainly through blood vessel. 
For the avascular compartment, e.g., an avascular tumor, the drug transportation is mainly via 
diffusion in the stromal. The corresponding PBPK equations characterization the temporal evolution 
of C1 and C2 are given below: 
1 2
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where k21, k12, k10 are transport rate constants (for example, k21 is the transport rate from compartment 
2 to compartment 1); V1 and V2 are volumes of the compartments, d(t) is the time-dependent dosage as 
a drug source. Eq. (1) means that the change rate of C1 consists of the incoming flow from the 
compartment 2 (the first term); the outgoing flow (the second term) and the injection flow from the 
dosage source (the last term). 
Using the same set of model parameters and initial conditions given in Ref. 39 (see the values in 
the caption of Fig. 1(c)), we can calculate of the average drug (CPT-11) concentration as a function of 
time in the vascularized and avascular compartments, representing respectively a vascularized and 
avascular tumor environment, for a given dosing condition. Fig. 1(c) shows the results for an impulse 
dosing at t = 0. It can be seen that in both compartments, the average drug concentration decays 
monotonically with time and C1 in the vascularized compartment possessing a much higher initial 
value, also drops much faster than C2 in the avascular compartment. This is due to the different drug 
transport mechanism. These PBPK results are imply that the drug concentration in tumors in avascular 
micro-environments decays much slower than that in those in vascularized micro-environments, 
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although the initial concentration value in the avascular micro-environment is lower than that in the 
vascularized micro-environment for the same initial dosage.  
Based on the PBPK calculations, in our subsequent simulations, two distinct types of 
time-dependent boundary conditions characterizing the drug concentration at the boundary of our 
simulation domain will be used respectively for tumors in vascularized and avascular 
micro-environments. In particular, we consider that for the avascular micro-environment, the drug 
concentration has very slow decay after each bolus injection; and in the vascularized 
micro-environment, the drug concentration decays quickly after a bolus injection. On the other hand, 
for constant dosing, the drug is continuously supplied leading to an almost constant concentration 
level of the drugs in different compartments. 
2.2 Diffusion-reaction model for temporal-spatial evolution of drug concentration in tumor 
systems 
To simulate the temporal-spatial evolution of drug concentration in tumor systems, we employ the 
following diffusion-reaction model:  
                
2
0 0
0
metD K
t
 
  
 

   
 
                              (3) 
where D0 is the diffusion coefficient of the drug; the last two terms result from drug consumption. 
Specifically, the parameter Kmet is the first-order decay rate due to the chemical decomposition as the 
drug macromolecules diffuse in the stroma. The last term on the right hand side of Eq. (3), usually 
referred to as the Michaelis-Menten metabolism term 23,40, characterizes the drug up-take by tumor 
cells, i.e., drug concentration will decrease in the presence of the tumor cells, and we set 0 = 14n, 
where n is the tumor cell number density, which is computed from CA model as described below. 
We consider the simulation domain is initially drug free and the drugs enter the domain through 
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the boundary. For constant dosing, a time-independent drug concentration value will be used of the 
boundary condition. For periodic dosing, a general time-dependent boundary condition suggested by 
the PBPK calculations is employed to capture the time-evolution of drug concentration in the 
tumorous organ due to pharmacokinetics as well as different dosing cycles. Specifically, in the early 
stage of one dosing cycle, i.e., the drug infusion period characterized by the infusion time infusion, the 
drug concentration approximately remains a level in the system and then decays to zero after infusion as 
indicated by pharmacokinetics. This infusion-decay process corresponds to a complete dosing cycle 
with a period cycle and such a process is repeated to simulate periodic dosing. For different tumor 
micro-environment (i.e., vascularized vs. avascular), the rate of decay for the drug concentration is 
taken differently according the PBPK calculations. 
To numerically solve the diffusion-reaction equation (3), we use the finite difference method. In 
particular, the simulation domain containing the solid tumor and stroma is discretized into a cubic grid 
with 
3
fN  points. The Euler forward-finite difference scheme is used, i.e., 
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where the Laplacian operator for spatial finite difference is written as 
2
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This algorithm is numerically stable for the pure diffusion equation, if the following condition is 
satisfied 71 
                   0
2
1
2
D t
x



                                   (6) 
We have verified that Eq. (6) is also sufficient to guarantee numerically stability for Eq. (4). ni,j,k is the 
cell density from the CA model, as is described later. 
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The obtained drug concentration value on each grid point is then mapped to the nearest 
automaton cells, which is then used to determine the decrease factor for the division rate of the 
proliferative cells in the CA model. The number of automaton cells representing the tumor cells within 
the volume element associated with a grid point is also obtained and used to calculation the tumor cell 
number density n for Eq. (3). The detailed implementation for coupling the continuum 
diffusion-reaction model and the discrete CA model is provided in Sec. 2.4.  
2.3 Cellular automaton model for invasive tumor growth in heterogeneous microenvironment 
under effects of drugs 
We employ the cellular automaton (CA) model to simulate the evolution of invasive tumor in 
heterogeneous microenvironment under the effects of chemotherapy. Our CA algorithm follows 
closely that described in Refs. 27 and 28. In particular, the simulation domain is tessellated into 
polyhedra (or polygons in 2D) associated with a prescribed point configuration (i.e., the centers of 
randomly packed congruent hard spheres) via Voronoi tessellation. Each polyhedron is defined as an 
automaton cell, which in our model can either represent a real biological cell or a region of tumor 
stroma (which consists of a cluster of ECM macromolecules). The tumor cell can be proliferative, 
quiescent, necrotic or invasive in our model (see details below). Accordingly, the tumor-associated 
automaton cell can take distinct numerical values representing the different tumor cell state. Each 
ECM-associated automaton cell possesses a local density value ECM to take into account the ECM 
heterogeneity, which is also positively correlated with the local ECM rigidity. When an 
ECM-associated automaton cell is taken by a tumor cell due to either proliferative growth or invasion, 
we set its ECM = 0. 
In our simulation, the tumor cells in the proliferative rim (mainly in the outer shell of the 
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primary tumor which has access to the nutrients such as oxygen and glucose) can produce daughter 
cells taking nearby ECM-associated automaton cells via cell division. This process leads to the growth 
and expansion of the primary tumor mass. The tumor cells in the inner region may turn into quiescent 
(alive but inactive) and then necrotic (dead) if they could not acquire sufficient nutrients for a long 
time. A small fraction of daughter cells may acquire invasive phenotype (e.g., weak cell-cell adhesion, 
strong mobility and ECM degradation ability) via mutation, which can leave the main tumor body and 
immigrate into the surrounding tissue leading tumor invasion. In our simulation, time is discretized 
into days, and for each day, the state of all tumor cells are checked for possible update. During each 
day, the evolution of the tumor is simulated by applying the following cellular automaton (CA) rules: 
1. The quiescent cells more than a certain distance  n from the tumor surface are turned necrotic 
due to starving. The critical value of  n is given as 
         
 1d d
n taL

                                   (7) 
where a is a prescribed scaling parameter (see Table 1) and d is the spatial dimension. Lt is the 
distance between the geometric centroid (xc) of the tumor and the tumor edge cell that is 
closest to the quiescent cell considered. xc is defined as 
1
1
N
c iN i
 

x x , where N is the total 
number of noninvasive tumor cells, which is updated when a new noninvasive daughter cell is 
added to the tumor. 
2. Each proliferative cell can produce a daughter cell the probability Pdiv, which will occupy an 
ECM-associated automaton cell in the surrounding stroma. We consider that the probability of 
division depends on both the heterogeneous environment and local drug concentration and 
possess the following expression 27,28 
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where p0 is the base probability of division, P, is the cellular division reduction factor due to 
the chemotherapy and is considered a linear function of normalized local drug concentration 
() , i.e., P, = 1 – (1- P) ; r  is the distance of the dividing cell from the tumor centroid; 
Lmax is the distance between the tumor centroid and the closest growth-permitting boundary 
cell in the tumor growth direction. Eq. (8) implies that Pdiv depends on both the physical 
confinement imposed by the boundary of the growth-permitting region and the local 
mechanical interaction between tumor cell and the ECM, as well as the local drug 
concentration. 
3. A proliferative cell turns quiescent if it is more than a certain distance  p from the tumor 
surface or there is no space for the placement of the forthcoming daughter cells. The distance 
 p, which corresponds to the thickness of nutrient-rich proliferative rim of the primary tumor, 
is given by 
( 1)/d d
p tbL
                                (9) 
where b is a prescribed scaling parameter (see Table 1), Lt is the distance between the tumor 
centroid and the tumor edge cell that is closest to the proliferative cell considered. 
4. A newly produced daughter cell can gain invasive phenotype (weak cell-cell adhesion, high 
motility and strong ECM degradation ability) and become an invasive cell with the mutant 
probability  (see Table 1). 
5. A mutant invasive cell has the ability to degrade the nearby ECM and migrate into the 
surrounding stroma. We consider that the invasive cell has the mobility: , which is the upper 
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bound on the number of attempts the cell makes to degrade the surrounding ECM and migrate 
into the ECM-associated automaton cell. For example, an arbitrary invasive cell can make m 
attempts to degrade ECM and move, where m is an arbitrary integer in [0, ]. In each 
degradation/moving attempt, the density of the ECM-associated automaton cell will be 
decreased by  p , where  p is an arbitrary real number in [0, ] characterizing the cell’s ECM 
degradation ability. After m attempts, if the ECM in the automaton cell is completely 
degraded (ECM  0), the invasive cell will migrate into this automation cell, leaving behind a 
path composed of degraded ECM-associated cells. The direction of motion is the one that 
maximizes the nutrient concentration.  
6. A migrating invasive cell does not divide anymore. 
 
Symbols Definition Expression or values 
tL  
Local tumor radius (varies with cell positions) See the text 
maxL  
Local maximum tumor extent (varies with cell positions) See the text 
a  Base necrotic thickness 0.12 
b  Base proliferative thickness 0.08 
0p  
Base probability of division 0.192 
n  
Characteristic living-cell (necrotic cell) rim thickness See Eq. (7) 
p  
Characteristic proliferative rim thickness See Eq. (9) 
divP  
Probability of division for proliferative cells See Eq. (8) 
  Mutation rate for invasive cells 0.05 
  ECM degradation ability 0.15 
  Mobility of invasive cells 3 
Table 1. Summary of the definition and numerical values of the parameters for the CA model. 
 
2.4 Spatial-temporal coupling of the diffusion-reaction and cellular automaton models 
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In order to investigate the effects of chemotherapy on tumor growth, one needs to couple the 
diffusion-reaction model describing the drug diffusion and consumption with the CA mode for tumor 
dynamics. Although the spatial coupling of the two models is straightforward by mapping the 
computational grid points for PDEs to the CA cell positions, the temporal coupling can be nontrivial.  
We first estimate the characteristic drug diffusion time in the tumor. From the analytic solution 
of diffusion equation in a homogenous medium:  
2
4
3
1
( , )
(4 )
r
Dtr t e
Dt



  for the initial condition 
( ,0) ( )r r  72, we can define a characteristic “diffusion time”
2
0
4
m
x
t
D
 , at which the concentration at 
x0 is high enough (about 
1 0.37e   compared to that at the source).  If we set D = 1.3  10-6 cm2s-1, 
x0 = 0.3 cm, we see tm = 1.73  104 s, or about 0. 2 day. If we set D = 1.3  10-7 cm2s-1, x0 = 0.3 cm, 
we have tm = 1.73  105 s or about 2 days. Comparing the common cell cycle time (ranging about 8 
hours to 24 hours), we see that for the ordinary drug, the characteristic diffusion time is typically less 
than one cell cycle.  
The above analysis suggests that the drug can diffuse rapidly into the tumor, and thus the drug 
concentration may change significantly in one cell cycle due to cellular uptake of the drug 
macromolecules and metabolism. However, the traditional CA model usually sets the cell division rate 
(Pdiv) as a constant in one cell cycle. So in our hybrid model, it is not suitable to do the drug diffusion 
calculation between two cell cycles. In the actual system, drug diffusion and cell division occur 
simultaneously and can have instant effects on one another: the drug reduces the cell division rates 
and the growing tumor result in drug consumption and variation of the diffusion coefficient.  
In our model, we develop a quasi-parallel algorithm for coupling these two processes: We 
divide one cycle of the proliferation process (during which cell divides) and one dosing period (during 
which the drug diffuses into the tumor mass) into the same number of (Np) steps. In each step, these 
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two dynamical processes are simulated in sequence for different iterations. Then at the end of each 
step, the updated drug concentration distribution obtained from the diffusion-reaction model is passed 
to the CA model to compute updated cell division reduction factor; and the updated cell density 
distribution and heterogeneous diffusion coefficient distribution obtained from the CA model are 
passed to the diffusion-reaction model. Figure 1 (d) schematically illustrates this procedure. We note 
that the aforementioned procedure not only enables easy parallelization of our hybrid algorithm but 
also more realistically mimics the actual tumor proliferation process compared to traditional CA 
method. In particular, in traditional CA method, the fact that tumor cells divide at different times 
within a proliferation cycle is not explicitly considered. Here, by coupling a sub-spatial region of the 
tumor with a sub-temporal process of drug diffusion, we consider that the cells within this sub-region 
divide during the time span in which the diffusion occurs. This implies that tumor cells in different 
sub-region divide at different times. When Np is sufficiently large (e.g., = 50 ~ 100), the quasi-parallel 
algorithm can approximate the actual coupled processes. At last, we notice that in this coupling 
algorithm, we calculate the cell density in CA model by the expression: 
, ,
1
i j k m
m
n n
V


 , where nm =0 
or 1, for all the tumor cells in the neighbor of a finite difference grid point (i,j,k) , V is the unit 
volume of the grid. This is used in the consumption calculation for Eq. (4). We use a mapping scheme 
to relate these quantities (such as ni,j,k, , ,
n
i j k , ,( , , )
n
ECM i j k ) between the finite difference grid and the 
Voronoi tessellation. 
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Fig. 1 Schemes of the tumor-drug model and the time-dependency of drug concentration. (a) and (b): 2D 
schematic illustrations of the tumor-drug models in this paper for the avascular tumor in an avascular (a) and  
vascular (b) host micro-environment, respectively. The Voronoi polyhedral in the figure is used in the CA model. 
The necrotic cells are black, quiescent cells are yellow, proliferative cells are red and the invasive tumor cells 
are green. The ECM associated automaton cells are white and the degraded ECM is blue. And the overlapped 
square grid (blue) is used in the finite difference calculation for the drug diffusion. (c) The drug (CPT-11) 
concentration dependence on time in the plasma (C1) and the avascular tumor (C2) calculated by the 
two-compartmental PBPK model (Eq. (1)-(2)). The parameters used in the calculation are: k21 = 1.48 day-1; k12 = 
0.276 day-1; k10 = 13.27 day-1; V1 = 4.85  103 ml; V2 = 8.0  103 ml. The initial condition att= 0 is set as C1 = 
1.0 g/ml and C2 = 0.2 g/ml. (d) Schematic illustration of the hybrid-parallel algorithm coupling the drug 
diffusion/consumption and cell division processes. The Fortran commands (do i = 1, N; enddo) in the rectangles 
indicate the loops in our algorithm.  
3. Results and Discussions 
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In this section, we first study the drug dynamics in a steady-state tumor (i.e., with constant cell density 
distribution), in order to understand the spatial-temporal evolution of drug concentration within one 
proliferation cycle for both constant dosing and periodic dosing conditions. Then we employ the 
model to investigate the growth of avascular tumors in both vascularized and avascular homogeneous 
environments under constant and period dosing conditions. Finally, the coupled hybrid model is 
employed to study the effects of periodic dosing conditions on invasive tumor growth in 
heterogeneous microenvironment. 
3.1 Spatial-temporal evolution of drug concentration in steady-state tumors 
3.1.1 Drug dynamics in steady-state tumor with constant dosing condition  
      In the constant dosing condition, the boundary condition is set as a time-independent constant 
in the outer spherical shell (with the radius R = 0.4 cm) without any decay due to pharmacokinetics 
and is zero within the tumor region. In addition, we assume that stead-state tumor possess an ideal 
isotropic morphology, and tumor cell density distribution as one moves away from the tumor center 
can be characterized by a Fermi function (1/(1 + exp[(r - r0)/]), where r0 is the tumor radius and  is 
the effective boundary-layer thickness.  
The diffusion-reaction equation (3) is employed to obtain the drug concentration distribution as 
a function time. In particular, we consider tumors with different sizes r0 and drug consumption ratio 
λ14. Fig. 2(a) and (b) show respectively the distribution of drug concentration in a steady-state tumor 
with r0 =0.2 cm and  = 0.01cm at t = 100 minutes and t = 5 hours for different consumption ratios 
(14 = 2.5  10-4 s-1, 14 = 2.5  10-5 s-1 and 14 = 0). When there is no consumption, the evolution of 
the drug concentration is entirely controlled by the diffusion and chemical decomposition (Kmet) terms, 
and the concentration values in the inner tumor region is larger compared to the other two cases. In 
18 
 
addition, it is clear that a larger consumption ratio leads to a lower drug concentration in the inner 
tumor region. The long-time drug concentration shown in Fig. 2(b) represents steady-state solution to 
Eq. (3). We note that the typical time to achieve this steady-state (5 hours in the current case) is faster 
than a typical cell proliferation cycle, which is consistent with our time-scale analysis discussed in 
Sec. 2.4. Fig. 2(c) shows the drug concentration distribution in a smaller tumor (r0 = 0.06 cm and  = 
0.01 cm) as a function of time with a large drug consumption ratio 14 = 2.5  10-4 s-1. Compared to 
Fig. 2(b), the steady-state of drug concentration distribution is established in a longer period of time, 
i.e., at t = 1000 minutes. This suggests that drugs need to diffuse through a wider region to achieve a 
steady distribution. Due to fast diffusion of drug and rapid establishment of the steady-state of drug 
concentration in the tumor region, we may approximate the actual drug distribution as a uniform 
constant for the constant dosing condition, as shown in later Sec. 3.2.1. 
 
Fig. 2 Spatial-temporal evolution of the drug concentration in the tumor model. (a) and (b) the drug 
concentration distribution in an ideal tumor with r0 = 0.2 cm and  = 0.01 cm. Under constant dosing condition 
with different drug consumption ratios, the concentration distribution is plotted at t = 100 minutes (a) and 5 
hours (b), respectively; (c) the drug concentration distribution in an ideal tumor with r0 = 0.06 cm and  = 0.01 
cm as a function of time with a large drug consumption ratio 14 =2.5  10-4 s-1 under constant dosing condition. 
The model parameters are set as follows: diffusion coefficient D0=1.3  10-6 cm2s-1; chemical decomposition 
ratio Kmet =2.0  10-4 min-1. t = 0.1 s; x  0.01 cm. The red lines are the corresponding cell density. 
3.1.2 Drug dynamics in steady-state tumors with periodic dosing condition 
We now consider the periodic dosing condition and employ a time-dependent periodic boundary 
condition to simulate the dosing condition 36. For the periodic dosing, due to different 
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pharmacokinetics in vascularized and avascular host micro-environments (see discussion in Sec. 2.1), 
we will consider these two cases separately. In particular, for the vascularized micro-environment, the 
drug is transported to the tumor region by blood vessels. For the avascular micro-environment, the 
drug reaches the tumor region mainly via diffusion. In the former case the drug concentration decays 
very quickly with an initial high very; and in the latter case, the drug concentration decays relatively 
slowly. In our simulation, we model these two cases by using different decay time parameters in the 
time-dependent boundary condition. Specifically, we assume that the drug concentration has the 
following time dependency 
      0( ) ,          [ , ( 1) ]
1 exp[( ) / ( /10)
cycle cycle
decay decay
C
C t t N N
t
 
 
  
 
          (10) 
where cycle is the dosing period and decay is the decay time for the drug in the tumor (for taking into 
account the pharmacokinetics effects).  
Fig. 3 shows the spatial-temporal evolution of drug concentration in ideal isotropic tumors with 
r0 =0.2 cm and  =0.01cm for both vascularized [(a) and (b)] and avascular [(c) and (d)] 
micro-environments under different periodic dosing conditions. Specifically, two periodic dosing 
conditions are applied, which are shown as the black curves in Fig. 3. We clearly can see that in the 
vascularized micro-environment, the drug decays rapidly (decay = 600 mins) and in avascular 
micro-environment the drug decays slowly (decay = 1800 mins). Moreover, in the avascular case, the 
drug is difficult to escape due to the pharmacokinetic analysis as shown in the black curves (on the 
tumor boundaries), the average drug concentration within the tumor always maintains in a relatively 
high level. This gives a positive effect on chemotherapy. Due to the decomposition and the small decay 
(600 mins) leads to a very rapid decay of the drug concentration in the tumor, consistent with the 
pharmacokinetic analysis (see Fig. 1b). In an avascular micro-environment, the large decay time (decay 
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=1800 mins) leads to a slow decay of the drug within the tumor. Moreover, in the avascular case, the 
average drug concentration within the tumor always maintains in a high level. Due to the diffusion 
and consumption, the drug concentrations in the central tumor region exhibit smaller values as shown 
by the red dashed curves in Fig.3. With smaller drug consumption, the maximum concentration in the 
tumor center is larger, which is consistent with the cases for constant drug dosing conditions. Finally, 
we observe that there is a phase shift for the periodic variation of dosage (black curves) and drug 
concentration in the tumor (red curves). This is because that drug needs some time to diffuse from the 
outer boundary to the inner region. 
 
Fig. 3 Spatial-temporal evolution of the drug concentration in ideal isotropic tumors under different 
periodic dosing conditions.  (a) and (b) are associated with the vascularized micro-environment with quick 
drag decay (decay = 600 min); (c) and (d) are associated with the avascular micro-environment with a slow drag 
decay (decay = 1800 min). (a) and (c) are associated with a small drug consumption ratio (14 = 2.5  10-5 s-1); (b) 
and (d) are associated with a large drug consumption ratio (14 = 2.5  10-4 s-1). The chemical decomposition 
parameter is the same in all cases: Kmet = 2.5  10-4 min-1. The black curve indicates the applied time-dependent 
boundary condition and the red curve indicates the drug concentration in the tumor center region. The dosing 
period is set as decay = 1 day = 1440 min. The tumor size parameters are set as r0 = 0.2 cm and  = 0.01 cm. 
3.2 Evolution of invasive tumors in homogeneous microenvironment under chemotherapy 
3.2.1 Invasive tumor growth under constant dosing condition   
We now employ the hybrid model to study the growth dynamics of invasive tumor under constant 
dosing condition in homogeneous microenvironment. To simulate the constant dosing condition, we 
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apply a time-independent constant drug concentration at the boundary of the simulation domain. As 
discussed in Sec. 3.1.1, in this case, the drug concentration evolution is the same for both vascularized 
and avascular micro-environments as the pharmacokinetics does not play a role here. The effects of 
different drug concentrations are taking into account by using different cell division reduction factor 
0
P
 (= 0.6 and 0.3). Here P, in the CA rule 2 in Sec. 2.3 is spatial independent, P, = 
0
P ). We chose 
the cell cycle time as one day. In the subsequent simulations, we focus on the early growth stages of 
the tumor. 
The growth dynamics of proliferative tumors, i.e., the tumor size (radius) as a function of time 
is shown in Fig. 4(a). We can see that when the drug is infused in the tumor, its growth is significantly 
suppressed. Higher drug concentration (i.e., associated with a larger of division reduction 
0
P ) leads 
to the slower growth of the tumor. This is expected as the drug can significantly suppress the division 
of proliferative cells which is a determinant factor for the tumor growth process.  
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Fig. 4 Tumor size and morphology under constant dosing condition. (a) The growth dynamics of 
proliferative tumors with different drug concentrations in homogeneous microenvironment. (b) The average 
sizes of invasive tumor cells as a function of growth time without chemotherapy. (c) The average sizes of 
invasive tumor cells as a function of growth time with a division reduction factor 0P = 0.6. (d) A snapshot of 
the simulated growing tumor without chemotherapy on day 120 (with 142 invasive cells); (e) A snapshot of the 
simulated growing tumor under constant dosing condition ( 0P = 0.6) on day 120 (with 31 invasive cells). As 
stated in the context, in this figure the micro-environment can be either avascular or vascularized. In (d) and (e), 
only the proliferative cells (red), the invasive cells (yellow) and the degraded ECM cells (cyan) are plotted. 
Next, we consider invasive tumor growth under the constant dosing condition with a high drug 
concentration (
0
P  = 0.6). The mutation rate and mobility of the invasive cells are respectively set as 
0.05 and 3 following Ref. 28. The ECM degradation ability is 0.4. Fig. 4(b) and (c) shows the average 
linear size associated with the quiescent region, proliferative rim and invasive branches as growth 
time for a freely growing invasive tumor and one under chemotherapy for purposes of comparison. 
Snapshots of the morphology of the growing invasive tumors are also shown in Fig. 4(d) and (e).   
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We can see from Fig. 4(b) and (c) that when the drug is applied, the expansion of both the 
proliferative tumor and the invasive cells are apparently surprised. A more quantitative comparison 
shows that although proliferative cells grow much slower (the final primary tumor size is decreased 
by 50%) with drug infusion, the growth of the invasive cells is only weakly suppressed (the final 
extent size is decreased by 20%). In the chemo treated tumors, the invasive cells can still develop long 
invasive branches (see Fig. 4(e)) compared to the free growth case. The apparent decrease of the 
overall extent of the invasive branches is due to the significantly reduced size of the primary tumor. In 
fact the average linear extent of the invasive cells remains roughly the same as in the free growth case. 
This is because the drug does not affect the motility and ECM degradation of the invasive cells. 
However, the number of invasive cells is reduced by applying the drug, which is again due to the 
reduced division rate of the proliferative cells (i.e., less mutant daughter cells with invasive phenotype 
are produced). 
3.2.2 Invasive tumor growth under periodic dosing condition 
We now investigate the effects of drugs on the tumor growth under periodic dosing condition. In this 
condition, drugs are periodically applied and the drug concentration decays in a different manner in 
vascularized and avascular micro-environments as predicted by the pharmacokinetic calculations. 
Specifically, for the vascularized micro-environment, the drug concentration at the simulation domain 
boundary drops very quickly due to the fast transport via blood vessels; and for the avascular 
micro-environment, the drug concentration at the tumor boundary decays relatively slowly due to 
diffusion.  
Fig. 5(a) shows the growth dynamics of both proliferative and invasive tumors in vascularized 
micro-environment under periodic dosing conditions. The distribution of drug concentration within 
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the tumor during one proliferative cycle is discussed in Sec. 3.1.2. Different dosages are applied, 
which leads to different cellular division reduction factors i.e., P = 0.6; 0.3 and 0.05 used in the 
simulations. For purpose of comparison, we also consider the growth proliferative tumor without 
chemotherapy and with two different constant dosing conditions (P = 0.6 and 0.3).  
 
Fig. 5: Rumor size in homogeneous microenvironment under periodic dosing conditions. (a) Growth 
dynamics of the tumor in vascularized homogeneous microenvironment under different periodic dosing 
conditions. Effects of different dosages are modeled via different division reduction factor P, with a dosing 
period and decay time of decay = 1 day and decay =600 min, respectively. For purpose of comparison, the results 
for constant dosing with P = 0.6 and 0.3 as well as freely growing tumors are also shown. (b) Growth dynamics 
of the invasive tumor in avascular homogeneous microenvironment under different periodic dosing conditions. 
The dosing period cycle, decay time decay are shown in the figure. Here a division reduction factor P = 0.05 is 
used. The results for tumor in vascularized micro-environment with small decay time (cases 1 and 2) are also 
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shown for purpose of comparison with the tumors in avascular micro-environment (cases 3 and 4). The 
consumption parameters used are Kmet = 2.0  10-4 min-1, 14 = 2.5  10-4 s-1 (cases 1, 2, and 3) and 2.5  10-5 s-1 
(case 4).  
We can see from Fig. 5(a) that in general periodic dosing conditions do not lead to the strong 
suppression of tumor growth as in the constant dosing cases, even for the high drug concentration 
cases (with a division reduction factor P = 0.05). This is because for the periodic dosing, the drug 
concentration drops quickly in the vascularized micro-environment, which results in a weaker 
reduction of cellular division. This is to contrast with the constant dosing condition, which has been 
shown to be able to significantly suppress tumor growth in both vascularized and avascular 
micro-environments. However, such dosing condition can cause also damages to the normal cells and 
serious side effects. Thus, an alternative strategy is to infuse the drug more frequently with a shorter 
dosing period, as we will show below.  
The growth dynamics of an invasive tumor under periodic dosing condition with P = 0.3 is 
also shown in Fig. 5(a). We see that the growth curve of the primary tumor almost coincides with that 
of the proliferative tumor with the same P. This is because although the invasive cells leave the 
primary tumor and migration into surrounding tissues, the division rate of the proliferative cells in 
both cases are almost identical, leading to the same primary tumor sizes.    
We now investigate the effects of different periodic dosing conditions on the growth of invasive 
tumors in avascular micro-environment. Fig. 5(b) shows the growth dynamics of the primary tumor 
for different dosing period cycle and decay time decay but the same division reduction factor P = 0.05. 
As shown in Fig. 5(b), cases 1 and 2 are associated the small decay time (cycle > decay), corresponding 
to the tumors in vascularized micro-environment for which the drug concentration decays very 
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quickly due to fast pharmacokinetics. Cases 3 and 4 are associated with the large decay time, 
corresponding to the tumors in avascular micro-environment. It can be clearly seen that in the latter 
cases (i.e., avascular cases) the drug can effectively suppress the tumor growth. The reason is that for 
the avascular micro-environment the drug decay is much slower (also see Fig. 1(c)). This results in a 
higher drug concentration to suppress the tumor cell division. In addition, a large consumption 
parameter (14 = 2.5  10-4 s-1) is used for case 3, and a small consumption parameter (14 = 2.5  10-5 
s-1) is used for case 4. We see that with a smaller consumption parameter, the drug concentration can 
remain a higher for a longer time, which leads to continuously suppression of tumor cell division and 
thus, a smaller final tumor size. 
Finally we investigate the invasive tumor morphology under these periodic dosing conditions. 
Fig. 6(a) to (c) shows the snapshots of the growing tumors at day 120 under periodic dosing with 
different decay times, i.e., a fast decay with decay = 600 min for (a) corresponding to tumors in 
vascularized micro-environment; and a slow decay with decay = 1800 min for (b) and (c) 
corresponding to tumors in avascular micro-environment. We see that in all cases, there are a large 
number of dendritic invasive branches composed of collectively migrating invasive cells. Since the 
drug only reduces the proliferative cells’ division rate, the linear extents of the invasive branches in all 
cases are almost the same. The sizes of the tumors in avascular micro-environment in Fig. 6(b) and (c) 
are smaller than the tumors in vascularized micro-environment in Fig. 6(a), which is due to the higher 
effective drug concentration in the avascular systems. The small consumption in (c) also leads to a 
decreased size than that in (b). 
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Fig. 6 Snapshots of simulated tumors. In all these cases, the same dosing period cycle = 1 day, chemical 
decomposition parameter Kmet = 2.0  10-4 min-1, and division reduction factor P = 0.05 are used. Here only the 
proliferative cells (red), the invasive cells (yellow) and the degraded ECM cells (cyan) are plotted. (a)-(c): 
Snapshots of the simulated invasive tumors in homogeneous microenvironment under periodic dosing 
conditions at day 120. (a) is the tumor in vascularized micro-environment with a quick drug decay (decay = 600 
min) due to fast pharmacokinetics and a small consumption parameter (2.5  10-5 s-1); (b) is the tumor in 
avascular micro-environment with a slow drug decay (decay = 1800 min) and a large consumption parameter (2.5 
 10-4 s-1); (c) is the tumor in avascular micro-environment with a slow drug decay (decay = 1800 min) and a 
small consumption parameter (2.5  10-5 s-1).  (d)-(e): Snapshots of the simulated tumors in heterogeneous 
microenvironment (with a random distribution of ECM density). (d) The ECM density ranges from 0.1 to 0.5 
and with an average value of 0.3; (e) The ECM density ranges from 0.1 to 0.9 and with an average value of 0.5. 
3.3 Evolution of invasive tumor in heterogeneous environment under periodic dosing conditions 
In this section we employ our hybrid model to investigate invasive tumor growth in heterogeneous 
environment under periodic dosing conditions. To accurately capture the diffusion dynamics of drugs 
in the heterogeneous stroma, we explicitly utilize the location-dependent diffusion coefficient in the 
diffusion-reaction equation, i.e.,  
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The discretized form of the heterogeneous diffusion term in Eq. (11) is given below  
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The diffusion coefficient in a heterogeneous ECM depends on the local ECM density, which also 
represents the rigidity of the system in our model. Following the formulation of heterogeneous gas 
diffusion coefficient in systems with non-uniform pressures73, we use the following empirical 
expression for ( , )D r t  
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where D0 is the diffusion coefficient in the uniform ECM possessing a density of 0ECM, res is the 
residual density after the ECM is completely degraded by the invasive cells. In the following 
simulations, we employ a random distribution for the ECM density and choose 0ECM = 0.3, which is 
the value used for the homogeneous ECM in previous sections. And we choose res =0.1. In addition, 
we set  = 0.75 since the diffusion in the tumor region is evidently slower due to high cellular density 
than that in the ECM.  
In the heterogeneous environment, we use the following sinusoidal-like distribution to 
describe the initial (time=0) ECM density 
, , ,
1
( ,0)= | sin( ) |
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                             (14) 
where ECM,av is the average ECM density, ECM,flue is the ECM fluctuation amplitude, Lx(Ly, Lz) is the 
sinusoidal period. In our simulation, we set ECM,av =0.3 for Fig. 6(d) and ECM,av =0.5 for Fig. 6(e). 
Lx(Ly, Lz) is about L/60 or L/30, where L is the size of the cubic simulation box. 
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P  14  
(s-1) 
ECM  cycle
(day) 
decay
(min) 
PR
*1 
(cm) 
InvR
*2 
(cm) 
InvN
*3 
0.6 2.5*10-4 0.3 1 600 0.210 ------- -------- 
0.3 2.5*10-4 0.3 1 600 0.200 ------- -------- 
0.05 2.5*10-4 0.3 1 600 0.198 ------- -------- 
0.05 2.5*10-4 0.3 1 600 0.187 0.264 92 
0.05 2.5*10-4 0.3 2 1440 0.174 0.262 101  
0.05 2.5*10-5 0.3 1 600 0.158 0.236 72 (a) 
0.05 2.5*10-4 0.3 1 1800 0.106 0.210 25 (b) 
0.05 2.5*10-5 0.3 1 1800 0.076 0.182  9 (c) 
0.05 2.5*10-5 [0.1,0.5]  1 1800 0.119 0.165 28 (d) 
0.05 2.5*10-5 [0.1,0.9] 1 1800 0.091 0.118 16 (e) 
*1: The averaged radius of proliferative cells at day 120; 
*2: The averaged radius of invasive cells at day 120; 
*3: The number of invasive cells at day 120. 
Table 2: Summary of the model parameters for different periodic dosing conditions (the division decay 
factor Pγ; the consumption parameter 14; the two periodic dosage times cycle anddecay) as well as the 
growth data of tumors in both vascularized and avascular micro-environment (the averaged radius of 
proliferative cells and invasive cells Rp and RInv; the number of invasive cells NInv) on day 120 in the 
heterogeneous ECM. The brackets in the last column indicate the corresponding morphology plots in Fig. 
6. 
Snapshots of the morphology of both proliferative and invasive tumors growing in 
heterogeneous ECM with random density under periodic dosing are shown in Fig. 6(d) and (e). It can 
be clearly seen that in the heterogeneous ECM, the tumors develop rough and bumpy surface due to 
position dependent inhomogeneous cell division probability, as well as varying division reduction 
factors due to inhomogeneous drug concentration. This phenomenon has also been observed in the 
previous work for tumors growing in heterogeneous ECM with high rigidity 28.   
Table 2 provides a detailed summary of the model parameters for different periodic dosing 
conditions as well as the growth data of tumors in both vascularized and avascular 
micro-environments on day 120 in the heterogeneous ECM. We can clearly see that for periodic 
dosing, the treatment is more effective in suppressing tumors in avascular heterogeneous 
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micro-environment than that in vascularized heterogeneous ECM, consistent with the cases in 
homogeneous ECM. In addition, we find that denser and more rigid ECM (e.g., with average density 
0.5) leads to an overall smaller tumor. However, under the same dosing condition, the tumor growing 
in heterogeneous ECM becomes more malignant (with larger primary tumor size and more invasive 
cells) compared the tumor growing in homogeneous ECM with the same density (ECM = 0.3).  
We note that a high ECM density, on the one hand, can suppress tumor growth; and on the other 
hand, can slow down the drug diffusion to the tumor region, which promotes tumor growth. Therefore, 
the actual tumor growth dynamics in heterogeneous ECM is the outcome of these two competing 
effects. For the case of average ECM = 0.3, the diffusion of the drug is significantly slowed down 
while the density is not high enough to sufficiently suppress tumor growth, leading to a larger tumor 
compared with that in homogeneous ECM with the same density. For the case of an average ECM = 
0.5, the ECM density is large enough to suppress tumor growth even with very little drugs, and thus, 
results in a smaller tumor compared to that growing in corresponding homogeneous ECM. However, 
the invasiveness of the tumor growing in heterogeneous ECM with high density is significantly 
enhanced, which is consistent with the observation reported in Ref. 28.   
3.4 Tumor growth dynamics in heterogeneous environments and non-uniform dosing conditions 
To further demonstrate the utility and predictive capability of our hybrid model, we now examine the 
effects of periodic dosing on the growth dynamics of proliferative tumors in highly heterogeneous 
microenvironment. Specially, we consider two distinct cases for the environmental heterogeneities: (i) 
geometrically confined microenvironment and (ii) spatially non-uniform drug dosing.   
3.4.1 Effects of geometrically confined microenvironment   
Certain tumors such as ductal carcinoma in situ (DCIS) grow in a geometrically confined 
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microenvironment, which usually results in a highly anisotropic tumor shape. On the other hand, the 
heterogeneity of the microenvironment also significantly influences the diffusion of drugs to the 
tumor site. Here, we apply our hybrid model to investigate the effects of periodic dosing on 
proliferative tumors growing in confined environment. The effects of the environmental confinement 
are modeled by a discontinuous distribution of ECM density. In particular, we consider the simulation 
domain is composed of two equal-sized sub regions. The left sub region possesses a higher ECM 
density value (ECM = 0.6, e.g., to mimic the hard basal membrane) and the right region possesses a 
lower ECM density value (ECM = 0.2, to mimic soft tissue). The dosing period is τcycle = 1 day, and the 
drug decay constant is τdecay = 800 mins. The drug is released at the boundary of the spherical 
simulation domain with radius R = 0.3 cm (see Fig. 1), which imposes a uniform initial high drug 
concentration at (and outside) the simulation boundary and zero concentration within the simulation 
domain. An initial tumor of linear size 0.06 cm is introduced in the center of the domain. The drug 
diffusion coefficient, which is a function of ECM density and local cell density, is obtained using Eq. 
(13). 
      The spatial-temporal evolution of the drug concentration in the ECM-tumor system is obtained 
by numerically solving Eq. (11). Figure 7(a) shows the drug concentration distribution in the x-y plane 
associated with z = 0 at t = 1.0 hour. Due to the high ECM density (i.e., low drug diffusivity) in the 
left region of the simulation domain, a higher concentration is built up compared to that in the right 
region. This leads to an overall non-symmetric distribution of drug in the system. However, due to the 
small tumor cell population (and size) at this stage (shown as the red circle in Fig. 7(a)), the difference 
in drug concentration in the left and right region next to the tumor is relatively small. Figure 7(b) 
shows the distribution of the division reduction factor Pr, in the proliferative rim at t = 15 days. We 
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note that the observed fluctuations in Pr, is mainly due to the heterogeneous cell division time in our 
hybrid model. As discussed in Sec. 2.4, in our CA model we consider a proliferative cell can divide at 
any time during a dosing cycle, implying a random distribution of cell division time. Under periodic 
dosing condition, the drug concentration at a cell at the time of division is generally different from 
that of another cell, leading to the non-uniform distribution of Pr,.  
Figure 7(c) and (d) show the snapshots of the growing tumors (at t = 150 days) in the confined 
environment with two different cell division probabilities (p0 = 0.192 and 0.288). It can be clearly 
seen that the tumor develops a highly anisotropic shape, indicating the majority of proliferation occurs 
in the right low-density ECM region. On the other hand, protrusion-like structures are developed 
across the soft-hard ECM boundary, which is a key feature of microenvironment-enhanced 
malignancy. We note that even after 150 days, the protrusions remain relative compact. This is to 
contrast the elongated dendritic protrusions typically found in tumors growing in drug-free hard ECM 
[20, 21]. These observations illustrate the effects of drug treatment on proliferative tumor in confined 
microenvironment.  
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Fig. 7 Effects of geometrically confined microenvironment on proliferative tumor growth under 
periodic dosing (decay = 600 min, cycke = 1 day). (a) Asymmetric distribution of drug concentration 
in the x-y plane associated with z = 0 at t = 1.0 hour. the small red circle denotes the original tumor; (b) 
Distribution of the division reduction factor Pr,φ in proliferative cells in the x-y plane associated with z 
= 0 on day 15. The red dots denote the proliferative cells. (c) Snapshot of a proliferative tumor 
growing in the confined microenvironment with p0 = 0.192 on day 150; (d) Snapshot of a proliferative 
tumor growing in the confined microenvironment with p0 = 0.288 on day 150. In (a), (c), (d), the 
middle lines denote the interfaces between two different ECM densities (ECM is 0.6 in the left side 
and 0.2 in the right side) 
 
3.4.2 Effects of spatially non-uniform drug dosing   
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Finally, we consider the effects of spatially non-uniform drug dosing. This is motivated by the fact 
that at certain stage of development, tumor cells can produce vascular endothelial growth factor 
(VEGF) to recruit endothelial cells for angiogenesis. The newly formed blood vessels can transport 
both nutrients and drugs to the local tumor site close to the blood vessels. When sufficient amount of 
drugs are transported to the tumor site, its local growth can be suppressed. Based on these 
considerations, in our simulation, instead of considering uniformly distributed vascular network (or 
avascular drug diffusion) on the tumor boundary as shown in Fig. 1, we consider the blood vessels 
recruited by the growing tumor are located in the lower left region of the tumor-ECM system. This is 
implemented by releasing the periodically dosed drugs at the lower left of the spherical simulation 
domain. Here, we set the drug concentration on the lower left region as a source boundary condition, 
where ( , )r t  is the periodical function in Eq. (10) for only a restricted region, which satisfies the 
following conditions: (0.2 cm ≤ r ≤ 0.3 cm; x – x0 < 0; y – y0 < 0), where x0 = y0 = z0 = 0.5 cm, are the 
coordinates of the spherical center. 
      Figure 8(a) shows the distribution of drug concentration in the x-y plane associated with z = 0. 
It can be seen from Fig. 8(a) that after initial releasing, the drugs quickly diffuse to the entire system 
and are consumed and degraded. The lower left region of the domain remains to possess a relatively 
high drug concentration even after 16.8 hours of dosing, suggesting a high suppression of tumor 
growth in this region. Figure 8(b) shows the distribution of the division probability Pdiv of the 
proliferative cells with z = 0. It can be seen that the cells in the lower left region possess a much 
smaller division probability due to the high drug concentration in this region. Figure 8(c) and (d) show 
the snapshots of two proliferative tumors with different cell division probabilities (p0 = 0.192 and 
0.384) at day 150. It can be seen that the effects of drugs are more significant in the fast growing 
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tumor (Fig. 8(d)). Specifically, the cell division in the lower left region of the fast growing tumor is 
strongly suppressed by the high drug concentration, which results in a relatively flat edge in this 
region. On the other hand, the slowly growing tumor develops a relatively isotropic shape with a 
slightly flat edge in the lower left region.     
 
Fig. 8 Effects of spatially non-uniform drug dosing (decay = 600 min, cycke = 1 day) on 
proliferative tumor growth (ECM is 0.2 in the whole region). (a) Evolution of drug concentration 
distribution in the x-y plane associated with z = 0. The drugs are dosed in the lower left region of the 
spherical simulation domain periodically. Left panel: t = 2.4 hours; right panel: t = 16.8 hours. (b) 
Distribution of the division probability Pdiv in proliferative cells in the x-y plane associated with z = 0 
on day 15. The red dots denote the proliferative cells. (c) Snapshot of a slowly growing tumor with p0 
= 0.192 on day 150. (d) Snapshot of a fast growing tumor with p0 = 0.384 on day 150. 
4. Summary and Conclusions 
In this paper, we presented a comprehensive investigation of the effects of different chemotherapy 
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(i.e., constant vs. periodic dosing) on the growth dynamics of invasive tumors in both vascularized 
and avascular 3D heterogeneous microenvironment using a novel hybrid computational model. Our 
hybrid model integrates the physiologically based pharmacokinetic model for predicting overall drug 
concentration decay in different types of tumors, the continuum diffusion-reaction model for 
spatial-temporal evolution of the drug distribution in tumor-ECM system, as well as the discrete cell 
automaton model for invasive tumor growth simulation under effects of drugs. This model allows us 
to explicitly consider the effects of heterogeneous environment on drug diffusion, tumor growth and 
invasion as well as the drug-tumor interaction on individual cell level.  
We have employed the hybrid model to investigate the evolution and growth dynamics of 
avascular invasive solid tumors in both vascularized and avascular micro-environments under 
chemotherapy with both constant and periodic dosing. We find that constant dosing is generally more 
effective in suppressing primary tumor growth compared to periodic dosing, due to the resulting 
continuous high drug concentration. Moreover, periodic dosing is found to be more effective in 
suppressing tumor growth in avascular micro-environment, due to the slower pharmacokinetics in 
such systems. However, as the chemotherapy is assumed not to suppress invasive cell migration, 
complex invasion branches emitting from the primary tumor have been found. In addition, we find 
that the malignancy of the tumor is significantly enhanced in highly heterogeneous microenvironment, 
leading to inefficient chemotherapy. We also use this model to the geometry-confined environment 
and non-uniform drug dosing situation. Our computational model, once supplemented with sufficient 
clinical data, could eventually lead to the development of efficient in silico tools for prognosis and 
treatment strategy optimization. 
In our current model, the drug-tumor interaction is modeled as a reduction of the division 
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probability (rate) of individual tumor cells, which depends on the local drug concentration. We note 
that this treatment does not explicitly consider the heterogeneity in the distribution of cell division 
time and cycle time and has assumed uniform distributions for these quantities. In future, we will 
further generalize our hybrid model to explicitly take into account the aforementioned heterogeneity, 
which would lead to a more accurate prediction of tumor growth dynamics under periodic dosing 
conditions.    
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